Market Report, "Taiwan Pharmaceuticals & Healthcare Report Q3 2013", Published
Taiwan will continue to represent a modestly attractive proposition for drug manufactures. Our view is based on factors such as the maturity of its pharmaceutical market, government encouragement of generic medicines and authorities desire to reduce unnecessary use of medicines. For example, the Bureau of National Health Insurance (BNHI) in Taiwan is cracking down on prescription drugs waste by tightening its oversight of prescription drug distribution. Therefore, we envisage that main drivers of the Taiwanese pharmaceutical market development will be...
View full press release